hiv-1 in

HIV-1 inhibitor-54 is a potent inhibitor of WT HIV-1 (strain IIIB) in MT-4 cells, demonstrating anti-HIV activity with an EC50 of 32 nM. [HIV-1 inhibitor-54 can be used to study viral infections.]

HIV-1 integrase inhibitor 8 is an inhibitor of HIV-1 integrase, a critical enzyme necessary for the integration step in HIV replication [1].

HIV-1inhibitor-75 is a human immunodeficiency virus 1 (HIV-1) inhibitor with an EC50 range of 0.0039-0.338 μM. Its target is the reverse transcriptase, exhibiting an IC50 value of 0.055 μM. Additionally, HIV-1inhibitor-75 demonstrates good metabolic stability in vitro, presenting moderate clearance rates and an extended half-life in human plasma and liver microsomes.

HIV-1inhibitor-76 (compound 9t-2) is an inhibitor of the HIV-1 non-nucleoside reverse transcriptase. It is utilized in research aimed at combating HIV.

HIV-1inhibitor-80 (compound M44) is an HIV-1 inhibitor with an EC50 of 5-148 nM. It demonstrates excellent metabolic stability and low cytotoxicity in human plasma and liver microsomes.

HIV-1inhibitor-82 (Compound L14) is a small molecule inhibitor of HIV-1 entry with oral bioavailability, exhibiting an IC50 value of 0.39 μM. It holds potential for research in combating HIV-1 infection.

HIV-1integrase inhibitor 12 (Compound 17) is an inhibitor of HIV-1 integrase with an IC50 of 1.4 nM. It effectively inhibits both HIV-1WT and HIV-1T125A with IC50 values of 7.4 nM and 120 nM, respectively. This compound exhibits metabolic stability and Caco-2 permeability in rats, with favorable pharmacokinetic properties, including good bioavailability (64%) and low clearance rate (0.16 L/hr/kg).

HIV-1inhibitor-68 (compound 26) is a derivative that activates protein kinase C (PKC) and exhibits latency-reversing activity in HIV-1. It holds potential for eradicating cells latently infected with HIV-1.

HIV-1 inhibitor-47 is a compound that effectively inhibits HIV-1 by preventing the vif-dependent degradation of human APOBEC3G. It has a notable inhibition effect, with an IC50 value of 14.33 μM. Additionally, HIV-1 inhibitor-47 is involved in the synthesis of derivatives of 1-(2-pyrimidinyl)piperazine, which have the potential to exhibit antianxiety, antidepressant, and antipsychotic effects [1] [2] [3].

HIV-1 inhibitor-15 (compound 9d) is a potent, broad-spectrum inhibitor targeting HIV-1, with EC50 values of 1.7 nM against HIV-1 WT, 4 nM against L100I, 2 nM against K103N, 6 nM against Y181C, and 9 nM against E138K. It exhibits high efficacy, favorable solubility, safety profiles, and oral bioavailability [1].

HIV-1 inhibitor-35 (compound 74) is a highly potent inhibitor of the HIV-1 virus, exhibiting EC50 values of 80 nM and 70 nM for LTR and CMV, respectively, in HEK293 cells. Additionally, it demonstrates inhibitory activity against HepG2 liver cancer cells, with a CC50 value of 40 nM, and shows promise as a potential HIV-1 latency reversing agent [1].

HIV-1 inhibitor-31 (compound 4) is a potent inhibitor of HIV-1 and can be used in the study of AIDS.

HIV-1 inhibitor-33 (compound 5n) is a potent and selective HIV-1 inhibitor with an EC50 of 8.6 nM and a CC50 of 18 μM in MT-4 cells, and can be used in the study of AIDS.

HIV-1 inhibitor-24 (compound S-12a) is a potent inhibitor of HIV-1 reverse transcription (HIV-1 RT) with an IC50 of 9.5 nM. It exhibits a high antiviral effect on wild-type HIV-1, showing an EC50 value of 1.6 nM and low cytotoxicity (CC50 on MT-4 cells). HIV-1 inhibitor-24 was well tolerated in mice at a dose of 2 g/kg and demonstrated a significant cardiovascular safety profile.

HIV-1 inhibitor-40 (Compound 4ab), an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) with an EC50 of 1.9 nM, exhibits no significant acute toxicity in vivo and functions as a highly sensitive inhibitor of the orexin receptor antagonist CYP.

HIV-1 inhibitor-46 (compound 13d) is a potent non-nucleoside reverse transcriptase inhibitor of HIV-1 with an EC50 of 1.425 μM. This compound is suitable for use in AIDS research.

HIV-1 inhibitor-34 (compound 5q) is a potent and selective HIV-1 inhibitor, with an EC50 of 6.4 nM for HIV-1 and a CC50 of 16 μM in MT-4 cells, making it useful for AIDS research.

HIV-1 inhibitor-32 is a potent inhibitor of HIV-1 that acts on wild-type HIV (IC50: 34 nM) and can be used in AIDS research.

HIV-1 inhibitor-28 is a potent and selective HIV-1 inhibitor with EC50=58 nM for wild-type HIV-1, IC50=3.37 μM for wild-type HIV-1 reverse transcription, and relatively low toxicity to MT-4 cells with CC50= 38.6 μM. HIV-1 inhibitor-28 can be used in AIDS research.

HIV-1 inhibitor-29 is a potent inhibitor of HIV-1 and acts against HIV-1 IIIB (EC50: 2.18 μM). HIV-1 inhibitor-29 shows high resistance to the F227L/V106A strain with an EC50 value of 0.974 μM. HIV-1 inhibitor-29 showed low cytotoxicity against MT-4 cells with a CC50 value of 211 μM. HIV-1 inhibitor-29 can be used in AIDS research.

HIV-1 inhibitor-23 is a highly potent inhibitor of HIV-1 non-nucleoside reverse transcriptase, acting on both wild-type HIV-1 (EC50: 24.9 nM) and mutant strain K103N (EC50: 10.4 nM). microsomal stability in vitro.

HIV-1 Integrase Inhibitor 10, an orally active allosteric integrase inhibitor (ALLINI), effectively inhibits the NLRepRluc virus's viral outgrowth in MT-2 cells, exhibiting EC50 values of 3-5 nM. This compound is utilized in the research of Human Immunodeficiency Virus-1 (HIV-1).

HIV-1 Inhibitor-49, a HEPT analog, is an orally active non-nucleoside reverse transcriptase inhibitor with potent activity against HIV-1, demonstrating an IC 50 of 30 nM. It features an excellent pharmacokinetic profile and has shown to be potentially safe without acute toxicity in mouse models.

HIV-1 Inhibitor-57 (Compound 12g) is an antiviral agent that potently inhibits both wild-type and five common NNRTI-resistant strains of HIV-1, exhibiting EC50 values between 0.024 and 0.0010 μM. It achieves this efficacy by forming supplementary interactions with residues surrounding the binding site in the HIV-1 reverse transcriptase (RT) [1].